{"analyses":[{"ciLowerLimit":"0.14","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"9.03","estimateComment":"Comparison: \"Tertile 1 (without 2 year lag)\" and \"Never (without 2 year lag)\".","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.9141","paramType":"Odds Ratio (OR)","paramValue":"1.12","statisticalMethod":"Conditional Logistic Regression"},{"ciLowerLimit":"0.12","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"7.78","estimateComment":"Comparison: \"Tertile 1 (without 2 year lag)\" and \"Never (without 2 year lag)\". Adjusted for smoking, BMI, diabetes, neuropathic pain, back pain, epilepsy.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.9613","paramType":"Odds Ratio (OR)","paramValue":"0.95","statisticalMethod":"Conditional Logistic Regression"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"300"},{"groupId":"OG001","value":"2925"}]}],"title":"Never (with 2 year lag)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"}]}],"title":"Tertile 1 (with 2 year lag)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"6"}]}],"title":"Tertile 2 (with 2 year lag)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}],"title":"Tertile 3 (with 2 year lag)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"299"},{"groupId":"OG001","value":"2916"}]}],"title":"Never (without 2 year lag)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"8"}]}],"title":"Tertile 1 (without 2 year lag)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"}]}],"title":"Tertile 2 (without 2 year lag)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"8"}]}],"title":"Tertile 3 (without 2 year lag)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"300"},{"groupId":"OG001","value":"2935"}],"units":"Participants"}],"description":"Incident bone/joint cancer. Gabapentin (Gaba.) Exposure Description: With 2 year (yr) lag=Gaba. exposure from cohort entry to 2 yr prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer). Without 2 yr lag=Gaba. exposure from cohort entry to index date. Tertiles (T) with 2 yr lag: T 1 (0.1-30.0 grams \\[g\\]), T 2 (30.1-189.0 g), and T 3 (189.1-9600.0 g). Tertiles without 2 yr lag: T 1 (0.1-30.0 g), T 2 (30.1-189.0 g), and T 3 (189.1-11610.0 g). Inestimable OR and 95% CI when no gaba.-exposed cancer cases or controls at the exposure level.","groups":[{"description":"Patients with incident bone/joint cancer defined from READ/OXMIS codes in the years 1995-2008","id":"OG000","title":"Incident Bone/Joint Cancer Patients"},{"description":"Cancer-free control patients risk set matched with incident bone/joint cancer patients for sex, age at cohort entry (within two years), calendar year of cohort entry (within one year), and General Practice site","id":"OG001","title":"Matched Controls for Incident Bone/Joint Cancer Patients"}],"paramType":"NUMBER","populationDescription":"Cases \\& controls drawn from the GPRD study cohort. Entry into study cohort began January 1, 1993, or at time of GPRD registration if after Jan. 1, 1993. Follow-up ended December 31, 2008, or earlier if respective cancer was diagnosed or if participant left the GPRD for any reason including death. Participants with prior history of cancer excluded.","reportingStatus":"POSTED","timeFrame":"The case index date was the date of incident bone/joint cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as for the case.","title":"Number of Bone/Joint Cancer Cases and Matched Controls With the Indicated Cumulative Dose of Gabapentin","type":"PRIMARY","unitOfMeasure":"participants"}